Eli Lilly and Company Aktie News

MercadoLibre is the e-commerce and fintech leader in Latin America. Eli Lilly is already looking ahead to its next generation of successes both in and outside of the GLP-1 industry.

Chevron (CVX) is expected to extend its dividend growth streak to 39 years, but with a muted 3–4% increase amid lower oil prices. CVX's earnings remain under pressure from declining oil prices despite cost-saving initiatives and the Hess acquisition, leading to subdued dividend growth. Dividend increases in January will generally be modest, with select companies like Fastenal, S&P Global, and C...

Since early August, the world's most valuable pharmaceutical stock, Eli Lilly and Company NYSE: LLY, has put on a stellar performance. After tanking 14% on Aug. 7 due to poor clinical trial results, shares have gained a whopping 71% year-to-date.

This pharma player offers you safety and growth. The company is a leader in a market that may approach $100 billion by the end of the decade.

Eli Lilly is the clear leader in the burgeoning weight loss market. Its lineup and pipeline put it well ahead of even its closest competitor.

Analysts predict packaged food manufacturers and fast-food eateries may be pushed to alter more of their goods next year when newly licensed appetite-suppressing GLP-1 tablets become accessible in January 2026.

Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming obesity drug market before cheaper generic versions hit shelves in March next year.

The U.S. Centers for Medicare and Medicaid Services said on Tuesday it will negotiate drug pricing with manufacturers of GLP-1 medications to expand access to the drugs that help with weight loss.